Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
vTv Therapeutics Inc. (VTVT) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/11/2023 10-Q Quarterly Report for the period ended June 30, 2023
08/11/2023 8-K Quarterly results
Docs: "vTv Therapeutics Announces 2023 Second Quarter Financial Results and Provides Corporate Update"
07/20/2023 8-K Quarterly results
06/08/2023 8-K Submission of Matters to a Vote of Security Holders  Interactive Data
05/11/2023 10-Q Quarterly Report for the period ended March 31, 2023
05/11/2023 8-K Quarterly results
Docs: "vTv Therapeutics Announces 2023 First Quarter Financial Results and Provides Corporate Update"
04/26/2023 DEF 14A Form DEF 14A - Other definitive proxy statements:
03/06/2023 10-K Annual Report for the period ended December 31, 2022
03/06/2023 8-K Quarterly results
Docs: "Therapeutics Announces 2022 Fourth Quarter and Full Year Financial Results and Provides Corporate Update"
03/06/2023 3 Brown Barry K. (Chief Accounting Officer) has filed a Form 3 on vTv Therapeutics Inc.
02/01/2023 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Elizabeth Keiley Selected as Executive Vice President and General Counsel of vTv Therapeutics HIGH POINT, N.C., February 1, 2023 -- vTv Therapeutics Inc. , a clinical stage biopharmaceutical company focused on the development of orally administered treatments for type 1 diabetes , today announced the appointment of Elizabeth Keiley as Executive Vice President and General Counsel, effective immediately. “We welcome Betzy to vTv. Her years of legal expertise and deep experience in life sciences will be valuable to the vTv team,” said Paul Sekhri, President and Chief Executive Officer of vTv Therapeutics. “Her decades of experience in both private practice and corporate settings make her an ideal fit for this position. I am confident that we will benefit from her contributions and look forwar..."
01/06/2023 8-K Investor presentation
Docs: "THE STATEMENTS MADE IN THIS PRESENTATION MAY INCLUDE FORWARD"
12/23/2022 8-K Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing  Interact...
12/13/2022 4 Form 4 - Statement of changes in beneficial ownership of securities:
12/13/2022 3 Form 3 - Initial statement of beneficial ownership of securities:
12/13/2022 8-K Quarterly results
11/30/2022 4 Form 4 - Statement of changes in beneficial ownership of securities:
11/10/2022 10-Q Quarterly Report for the period ended September 30, 2022
11/10/2022 8-K Quarterly results
Docs: "Agreements with CinRx Pharma and"
08/23/2022 SC 13G Medpace Investors, LLC reports a 5.2% stake in vTv Therapeutics Inc.
08/18/2022 4 Isaacsohn Jonathan (Director) has filed a Form 4 on vTv Therapeutics Inc.
Txns: Granted 50,000 options to buy @ $1.29, valued at $64.5k
08/18/2022 3 Isaacsohn Jonathan (Director) has filed a Form 3 on vTv Therapeutics Inc.
08/17/2022 4 Harris Keith R. (Director) has filed a Form 4 on vTv Therapeutics Inc.
Txns: Granted 25,000 options to buy @ $0.69, valued at $17.3k
08/17/2022 3 Harris Keith R. (Director) has filed a Form 3 on vTv Therapeutics Inc.
08/15/2022 10-Q Quarterly Report for the period ended June 30, 2022
08/15/2022 8-K Quarterly results
08/15/2022 8-K Quarterly results
08/08/2022 3 Form 3 - Initial statement of beneficial ownership of securities:
07/27/2022 8-K Quarterly results
07/25/2022 8-K Quarterly results
07/15/2022 4 Form 4 - Statement of changes in beneficial ownership of securities:
07/15/2022 8-K Quarterly results
07/06/2022 4 Weiner Howard L. (Director) has filed a Form 4 on vTv Therapeutics Inc.
Txns: Granted 105,128 options to buy @ $0.72, valued at $75.7k
07/06/2022 4 Form 4 - Statement of changes in beneficial ownership of securities:
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy